Extension of a predictive substrate model for human cytochrome P4502D6

Area of Science:

• Pharmacology
• Biochemistry
• Drug Metabolism

Background:

• Cytochrome P4502D6 (CYP2D6) is a key enzyme in drug metabolism.
• Understanding CYP2D6 substrate specificity is crucial for predicting drug interactions and efficacy.
• Existing models for CYP2D6 substrates have limitations in accurately predicting binding interactions.

Purpose of the Study:

• To develop and validate a small molecule model for predicting substrates of human cytochrome P4502D6.
• To assess the model's ability to differentiate between CYP2D6 substrates and non-substrates.
• To refine the model by incorporating known substrate binding characteristics.

Main Methods:

• Computational modeling of small molecules.
• Fitting various clinical compounds, including metoprolol, indoramine, codeine, tamoxifen, prodipine, and MDMA (ecstasy), into a substrate model for human cytochrome P4502D6.
• Evaluating the fit of R- and S-enantiomers of metoprolol and MDMA, as well as indoramine and codeine.
• Assessing the fit for tamoxifen and prodipine, where CYP2D6 involvement is uncertain.
• Extending the substrate model based on known large substrates.

Main Results:

• An acceptable fit was achieved for known CYP2D6 substrates: R- and S-enantiomers of metoprolol and MDMA, indoramine, and codeine.
• Tamoxifen and prodipine, with uncertain CYP2D6 involvement, did not achieve an acceptable fit within the model.
• Extension of the model did not alter the fundamental hydrophobic region crucial for substrate binding.

Conclusions:

• The developed small molecule model effectively predicts substrates for human cytochrome P4502D6.
• The model demonstrates potential for differentiating between true CYP2D6 substrates and compounds with uncertain involvement.
• The model's core hydrophobic region is critical for accurate substrate prediction.